大健康
UNIVERSAL HEALTH

UNIVERSAL HEALTH INTERNATIONAL GROUP HOLDING LIMITED
大健康國際集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2211)

PROFIT WARNING

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions under Part XIVA of the SFO.

The Board wishes to inform the shareholders and potential investors of the Company that, based on the preliminary review of the unaudited consolidated management accounts of the Group and the current available information to the Board, it is expected that the Group would record a loss of not less than RMB490 million (equivalent to approximately HK$536 million) for 2019/20.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

This announcement is made by Universal Health International Group Holding Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**SFO**").

The board of directors (the "**Directors**") of the Company (the "**Board**") wishes to inform the shareholders and potential investors of the Company that, based on the preliminary review of the unaudited consolidated management accounts of the Group and the current available information to the Board, it is expected that the Group would record a loss of not less than RMB490 million (equivalent to approximately HK$536 million*) for the year ended 30 June 2020 ("**2019/20**"). Details of which will be disclosed in the results announcement to be published in late September 2020.

The Board considers that the expected significant increase in loss recorded for 2019/20 as compared to the year ended 30 June 2019 ("**2018/19**") was mainly attributable to the following factors:

(i) Significant decrease in revenue resulting from, including, the economic downturn; the weakened purchasing power of the people living in the Northeast of the People's Republic of China; and the weakened consumer sentiment attributable to the outbreak of the novel coronavirus disease 2019 (COVID-19);

(ii) Increase in marketing and administrative expenses of products with exclusive distribution rights during 2019/20; and

(iii) The Group has made an analysis on the impact of the macro and industrial economic environment and performed an impairment assessment on goodwill and other related non-current assets. Basing on the signs of impairment, it is expected to make an impairment provision for goodwill and other related non-current assets.

Despite the expected significant increase in loss for 2019/20 as compared to 2018/19, the Group strives to strengthen its internet sales and marketing and promotion efforts to mitigate the adverse effects of the external environment.

Since the unaudited final results of the Group for 2019/20 have not yet been finalized and have not been reviewed by the audit committee of the Company, the information contained in this announcement is only based on the current available information and the preliminary unaudited consolidated management accounts of the Group, which are subject to finalization and, if any, adjustment. It is expected that the audited final results of the Group for 2019/20 will be announced in late September 2020.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Universal Health International Group Holding Limited
Jin Dongtao
Chairman

Hong Kong, 4 September 2020

As at the date of this announcement, the Board comprises four executive directors, namely, Mr. Jin Dongtao, Mr. Jin Dongkun, Mr. Zhao Zehua and Mr. Sun Libo and three independent non-executive directors, namely, Mr. Cheng Sheung Hing, Ms. Chiang Su Hui Susie and Mr. Zou Haiyan.

* *For illustrative purpose of this announcement, conversion of RMB into HK$ is based on the exchange rate of RMB1.00 = HK$1.09476 (published by The People's Bank of China on 30 June 2020).*